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Abstract 
Calcium/Calmodulin Dependent Protein Kinase Type-I1 Associates with 
Flightless-I to Influence its Nuclear Localization 
By Matthew E. Seward, B.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University 
Virginia Commonwealth University, April 2006 
Major Advisor: Robert M. Tombes, Ph.D., Associate Professor, Department of Biology 
~a~+/calmodulin-dependent protein kinase type-11 (CaMK-11) is a SerIThr protein 
kinase regulated by ca2+ and Calmodulin. It is a highly conserved and broadly expressed 
enzyme and has a unique structure and dynamic regulation. It has the ability to remain 
active in the absence of ca2+ as a result of ca2+ dependent autophosphorylation. CaMK- 
I1 phospliorylates proteins involved in neurotransmitter secretion, long term potentiation, 
cytoskeletal dynamics, gene transcription, and cell motility. To support existing and 
identify new intracellular roles of CaMK-11, potential binding partners were identified. 
This was accomplished by transfecting and purifying "FLAGu-tagged CaMK-11's (a, PE, 
Sc, and SE). CaMK-I1 associated proteins were then identified using tandem mass 
spectrometry. Known binding partners were identified using this approach, including 
CaMK-I1 and calmodulin, verifying the approach's validity. Additionally several 
unexpected but interesting proteins were identified, including the gelsolin related actin 
binding protein, Flightless-I. Fli-I is an actin binding and capping protein that also 
functions as a transcriptional coactivator. The CaMK-11-Fli-I interaction was confirmed 
with endogenous (un-tagged) proteins. The association and localization of Fli-I are 
dependent on CaMK-11's activity state, although Fli-I is not a substrate of CaMK-11. 
When CaMK-I1 is inhibited, Fli-I translocates to the nucleus. Conversely when CaMK-I1 
is artificially activated using a ca2+ ionophore, Fli-I returns to the cytosol. The discovery 
of this reversible interaction represents a potentially new CaMK-I1 regulated pathway and 
likely serves as a link between ca2+ based signal transduction pathways and regulation of 
the actin component of the cytoskeleton and transcription. 
Introduction 
CaMK-I1 Overview 
The role of ca2+ as a secondary messenger has long been established. A 
component of intracellular ca2+ signal transduction is the ~a~+/calmodulin dependent 
protein kinase type-I1 (CaMK-11) (Hudnion and Schulman, 2002b; Schulman, 1993). 
CaMK-I1 is conserved throughout metazoans and expressed in a wide range of cell types. 
It is encoded by four different genes (a, P, y, and 6) and is alternatively spliced to yield 
more than forty isozymes. Individual isozymes varies in expression by cell type and 
developmental progression and have unique localization patterns and presumably 
substrates (Mayer et al., 1993; Tombes et al., 2003; Tombes and Krystal, 1997; Zhou et 
al., 1995). 
CaMK-I1 Structure 
The CaMK-I1 holoenzyme consists of twelve subunits (six anti-parallel dimers) 
which arrange themselves in a unique fashion (Gaertner et al., 2004; Hunter and 
Scliulman, 2005; Kanaseki et al., 1991). From the amino terminus, each subunit has 
three major domains; a catalytic and regulatory domain, a variable domain and an 
association domain. The catalytic domain comprises the first 250 amino acid residues 
and includes the ATP- and substrate-binding sites. The regulatory domain encodes the 
autoinhibitory and calmodulin (CaM) binding regions over a 30 amino acid residue 
region (Kolb et al., 1998; Schulman and Lou, 1989). The variable region of CaMK-I1 
spans residues 3 15 to 345 up to 435, and is where alternative splicing occurs to generate 
isozyme variability. Splice variants are denoted by the Greek letter of the gene that they 
originate from followed by a subscripted capital letter representing the specific isozyme. 
The C-terminal association domain is required for the oligomerization of CaMK-I1 
monomers into dodecamers which is essential to CaMK-11's fi~nctionality. Dodecamers 
can be either homomeric or a heteromeric, consisting of either entirely one isozyme or a 
combination of multiple variants (Kolb et al., 1998; Lantsman and Tombes, 2005). 
CaMK-I1 Activation 
When the enzyme is inactive the autoinhibitory arm obstructs the active site 
preventing catalytic activity. When ca2+ rises, the ions are bound by the ca2+ binding 
protein CaM, which is then bound by CaMK-11, causing a relaxation of the inhibitory 
arm, exposing the active site (Mukherji and Soderliiig, 1994; Schulman and Lou, 1989). 
Partial activation of the enzyme increases its affinity for c a 2 + l c a ~ ,  raising CaMK-I1 
ca2+ sensitivity and excitability (Meyer et al., 1992). 
CaMK-I1 Autophosphorylation 
In addition to its ability to form a unique and complex quarternary structure, 
CaMK-I1 has the ability to autophosphorylate. The most important autophosphorylation 
site is ThSS7 in the regulatory domain. Autophosphorylation occurs in an intersubunit 
fashion between active adjacent subunits. An activated subunit can phosphorylate ThrZs7 
on another active adjacent subunit, preventing .the autoinhibitory arm from assuming its 
inhibitory confirmation. This phosphorylation frees CaMK-I1 of its c~ '+ /c~M 
dependence allowing it to remain active in their absence because the autoinhibitory 
domain is occluded from the active site regardless of their presence. This autonomy is 
one of Cam-11's most interesting features because it allows the enzyme to stay active in 
the absence of c a 2 + / c a ~ .  This condition is referred to as molecular memory and makes 
C a m - I 1  more dynaniically responsive to a variety of molecular conditions (Dunkley, 
1992; Dupont et al., 2003; Hudmon and Schulman, 2002a; Schworer et al., 1988). 
CaMK-I1 Function and Localization 
CaMK-I1 gene products have been sliown to play roles in various cellular 
functions and to be expressed in unique patterns. CaMK-11's role in the brain is well 
established and has been shown to have regulatory roles in a number of critical neural 
processes. a and p CaMK-11, for example, are regulators of neurotransmitter release 
through binding and phosphorylation of synaptic targets and are functional in both the 
pre- and postsynaptic densities (Benfenati et al., 1992; He et al., 2000; Yoshimura et al., 
2002). a CaMK-I1 is a regulator of long term potentiation and learning and memory 
through phosphorylation of a variety of neuronal receptors including AMPA and NMDA 
(Chen et al., 2001; Giese et al., 1998; Ito et al., 1991). a and P CaMK-I1 in nervous tissue 
localize to a variety of regions, varying by gene, but can be found in axons, dendrites, and 
cell bodies. Additional isozymes .that are expressed in the brain are encoded from tlie 6 
and y genes and are found in peripheral neural tissues, such as astrocytes and glial cells 
(Takaishi et al., 1992; Vallano et al., 2000). a CaMK-I1 is enriched in the frontal lobe of 
the brain and both P and 6 CaMK-I1 are enriched in the cerebellum. It is not surprising 
that CaMK-I1 is involved in so many processes because of its expression patterns, but 
also because of its ability to respond to a variety of ca2+ signals and transduce complex 
signals in an efficient manner (Chang et al., 2001; Erondu and Kennedy, 1985; Li et al., 
1998). 
Another well documented role of CaMK-I1 is in muscle. CaMK-I1 is expressed in 
cardiac, smooth, and skeletal muscle. y CaMK-I1 has been shown to be expressed in 
vascular smooth and heart niuscle. 6 isozymes regulate ca2+ levels in cardiac muscle and 
are involved in the regulation of ca2+ channels and the sarcoplasmic reticulum, all vital to 
maintaining regular heart beat (Abraham et al., 1996; Hoch et al., 1998; Hoch et al., 
2000; Singer et al., 1997). An interesting example of CaMK-I1 in muscle is of aKAP, a 
non-catalytically active form of a CAMK-I1 which is expressed in skeletal muscles and 
serves as an anchoring protein (Bayer et al., 1998; Takeuchi and Fujisawa, 1997). 
Developmentally, CaMK-I1 function is imperative, particularly in the brain. ca2+ 
transients are fundamental to successful organismal development, which makes CaMK-I1 
significant to the process. 6 CaMK-I1 isozymes have been shown to be expressed 
prominently during neural development (Faison et al., 2002). These isozymes are not 
expressed in the adult brain and are only expressed during early neural development 
(Bayer et al., 1999). Interestingly, a CaMK-11, the primary neuronal isozynie in the adult 
brain is not expressed until later in brain maturation. These are prime examples of the 
differential expression patterns of CaMK-I1 genes (Brocke et al., 1995; Burgin et al., 
1990). 
Additionally, roles for C a m - I 1  have been documented in transcription (Enslen 
and Soderling, 1994), cytoskeletal regulation (Shen et al., 1998; Takahashi, 2001), and 
niorphogenesis (MassC and Kelly, 1997). It is not unanticipated that it has such a diverse 
collection of functions, considering its intricate levels of regulation and unique structure. 
Its behavior is dictated by both c a 2 + / c a ~  dependent and autononious activity, pattern of 
isozyme expression, and homo- or hetero-oligomerization, which dictate its response to 
various types of ca2+ signals. Its capability to discern between ca2+ signal intensity, 
frequency, and duration and then transduce it enzymatically give CaMK-I1 a unique 
ability among protein kinases (Hudmon and Schulman, 2002b; Schulman et al., 1992). 
Although much information has been established on the role of CaMK-11, many 
of its substrates and binding partners have not yet been identified. Discovery of some of 
these targets would yield insight into CaMK-11's purpose in the cell. One approach that 
has been established as a method for identification of protein function is mass 
spectrometry. 
Tandem Mass Spectrometry 
An effective tool for identifying the complex patterns of protein-protein 
interaction is tandem mass spectrometry (MSMS) (Syka et al., 2004). Tliis technique 
allows for the identification of specific peptides from a complex solution. If a particular 
protein is isolated from cellular lysates any proteins that are associated with it are also 
captured. When these proteins are analyzed by MS/MS not only is the target protein 
detectable, so are the associated proteins. This narrows the list of candidate binding 
partners from the entire proteome to those detected in the analysis and yields insight into 
potentially uncharacterized functions. 
A tandem mass spectrometer differs from a single MS by coupling together 
multiple mass analyzers to sum their measuring capabilities to create a more accurate 
analysis of the sample (Busch et al., 1988). During a MSIMS analysis a sample of 
proteins in solution is reduced and denatured then digested with a protease, usually 
trypsin because of its efficient and consistent nature, which yields peptides of discrete 
size and charge. The sample is then introduced into a microcapillary HPLC which 
separates the peptide fragments by size. The fragmented peptides are then introduced into 
a highly charged electric field at a very slow rate creating highly charged droplets, a 
process called electrospray ionization (ESI) (Ashcroft, 2005). The droplets pass through 
a field of inert gas (most ofteii He) wliere they are disrupted by the collisioi~s with the gas 
molecules causing the solution to evaporate and the peptides to further fragment, at which 
point they enter illto an ion trap. A quadrupole ion trap captures peptides based on mass 
to charge ( d z )  ratio by establishing discrete gradients of charge, which suspends the 
peptides in space in distinct ndz ranges by electrically focusing them. Slowly each m/z 
group is released by a shift of the charge gradient in the trap and the peptides are released 
toward the detector, an electron multiplier (March and Todd, 2005). The detector 
analyzes each peptide it sei~ses and compiles a spectrum of the peptides. The scan is 
repeated, then the ten most abundant ions are selected and the cycle parameters are 
altered to screen the next ten most frequently appearing peptides. The scanning 
parameters are continuously redefined so only a small subset of the sample is being 
analyzed at any given time. This approach ensures the most accurate assessment of the 
proteins in the sample. 
A computer program called SEQUEST is used to analyze the experimental 
peptide sequences by comparing them to theoretical MSIMS spectra. The comparison is 
made to a database that contains hypothetical peptide sequences that could be created by 
protease digestion of every known protein, had they been digested in a manner similar to 
how the samples were prepared. The peptides in the database are assigned a score that is 
representative of the likelihood of each occurring based on the theoretical digestion. The 
score of each theoretical peptide is compared to the actual MS results to establish the 
validity of the data and from the analysis of the peptides a list of proteins is generated 
(Hernandez et al., 2006; Yates et al., 1995). 
CaMK-I1 Binding Partner Screen 
An MS/MS based screen for CaMK-I1 binding partners was undertaken. In order 
to partially purify CaMK-I1 from whole cell lysates, the "FLAG epitope system was 
used. FLAG is an eight amino acid residue epitope tag (DYKDDDK) which allows for 
efficient immunopurification of tagged proteins. The benefit of the FLAG system is that 
FLAG-tagged proteins can be easily eluted from anti-FLAG antibodies in a non- 
denaturing manner using a FLAG-peptide. The small peptide effectively disrupts the 
interaction between the FLAG tag and immobilized anti-FLAG IgG. The FLAG 
antibody is conjugated to agarose beads, which when stringently washed eliminates any 
non-specifically bound proteins leaving only FLAG-tagged CaMK-I1 and associated 
proteins. The FLAG elution approach adequately prepares samples suitable for MS/MS 
(Einhauer and Jungbauer, 200 1). 
For the binding partner screen, five FLAG-rnEGFP1CaMK-I1 (a, PE, ?jC, and full 
length and C-terminal tiE) fusion vectors were constructed and transfected into either NIH 
3T3 cells or into P19 neurons. NIH 3T3 cells are a well established mouse embryonic 
fibroblast cell line that is non-transformed, diploid, highly contact inhibited, and very 
transfectable (Copeland and Cooper, 1979; Jainchill et al., 1969). NIH 3T3 cells express 
CaMK-I1 endogenously, although primarily tjc. The P19 cell line is a diploid mouse 
embryonal carcinoma that can be induced to form neurons by treatment with retinoic acid 
(McBurney et al., 1982). P19 neurons express at least three different P and 6 CaMK-I1 
isozymes (Johnson et al., 2000). The transfected cells were harvested, and the FLAG 
tagged fusion proteins were immunopurified, eluted, and subjected to MSIMS analysis. 
Experimental Approach 
The CaMK-I1 binding partner screen generated a list of proteins which could be 
potential CaMK-I1 binding partners. It included a number of predicted proteins given 
CaMK-11's reported functions and previously established binding partners, in addition to 
a variety of unique and unanticipated proteins. 
One such unforeseen candidate was the gelsolin related actin binding protein 
(GRABP) Fligl~tless-I (Fli-I). Fli-I was first identified in Drosophila melanogaster, in 
mutant flies that had lost the ability to fly, but has been shown to have homologs in all 
metazoans. It is a developmentally essential actin binding and capping protein wit11 
transcriptional coactivity (Archer et al., 2005; Lee et al., 2004). This was a result that 
raised particular interest given the documented role that CaMK-I1 plays in regulation of 
the actin component of the cytoskeleton. 
The interaction between Fli-I and CaMK-I1 was pursued for this project. It has 
been speculated that Fli-I may serve as a link between several cellular pathways, 
including signal transduction pathways and regulation of the cytoskeleton through a yet 
to be identified protein (Davy et al., 2000; Fong and de Couet, 1999). It was hoped that it 
could be shown that CaMK-I1 is a factor in this signal transduction pathway through its 
interaction with Fli-I. Several questions were initially laid out to guide the study, 
including: 
Do endogenous CaMK-I1 and Fli-I interact? 
What is the nature of their interaction relative to CaMK-I1 activity? 
Does C a m - I 1  activity affect the localization of Fli-I? 
To answer these questions a number of approaches were taken. Antibodies 
against Fli-I and CaMK-I1 made it possible to confirm the interaction through reciprocal 
immunoprecipitations of endogenous proteins and also to perform immunolocalization 
experiments. Using different classes of CaMK-I1 inhibitors, media conditions, and 
constitutively active CaMK-I1 constructs I have characterized the nature of the Cam-11- 
Fli-I association. I have also found that CaMK-I1 and Fli-I interact in a manner 
dependent on CaMK-I1 activity which also affects Fli-1's cellular localization. 
Methods 
NIH 3T3 Cell Culture. 
NIH 3T3 cells were maintained in DMEM with 10% FBS, L-Glutamine, 
Penicillin, and Streptomycin at 37OC in a 5% C02  incubator in plastic tissue culture 
dishes (Nunc, Rochester, NY). Serum free experiments were in DMEM 
(Gibco/Invitrogen, Carlsbad, CA) with 0% FBS, L-Glutamine, Penicillin, and 
Streptomycin. 
PI9 Embryonal Carcinoma Cell Culture. 
Undifferentiated P19 cells were maintained in 10% FBS, L-Glutamine, Penicillin, 
and Streptomycin at 37OC in a 5% C02  incubator. They were induced to differentiate by 
treatment with 5x1 0-'M all trans retinoic acid (ATRA) at 1x1 o5 cells/ml in DMEM, 5% 
FBS, in bacteriological petri dishes for 4 days. The induced cells formed embryoid 
bodies, which were then plated at 2-5 x lo5 cells/cm2 on tissue culture dishes. Dishes 
were pre-coated with EHS laminin (0.1-0.5 pg/ml) in neurobasal medium containing N2 
supplement (Invitrogen) on day 0. 
Drug Treatment. 
The CaMK-I1 inhibitors, KN-93 and mAIP were used at a final concentration of 
10 pM and were added directly to cell cultures. The ca2+ ionophore, ionomycin was used 
at a final concentration of 1 pM. It was prepared as 1mL of 2 pM stock in serum free 
media then added to 1 mL of cells in culture. 
Cell Harvest. 
Cells were harvested by trypsin-EDTA and resuspended in Homogenization 
buffer with 30mM 4-(2-Hydroxyethy) piperazine-1-ethansulfonic acid (HEPES, pH 7.4), 
2.6 mM EGTA, 20mM MgC12, 80mM eglycerol phosphate, 0.1 pM okadaic acid, and 
10 pg/mL of chymostatin, leupeptin, aprotinin, pepstatin, and soy bean trypsiii inhibitor. 
The cells were sonciated on ice with two five seconds burst from a probe sonicator 
(Misonix, Farmingdale NY) and centrifuged at 4OC for 15 minutes at 12,000 x g. Protein 
concentrations were quantitated in triplicate with the BCA protein assays (Pierce, 
Rockford, IL) then immediately aliquoted and frozen at -80°C. 
FLAG-tag Fusion Vector Construction. 
The four full length CaMK-I1 isozymes in this study (a, PE, &, and &) had been 
previously cloned into the EGFP-C 1 vector (Clontech) as well as a C-terminal& 
construct, which is a truncated construct lacking the first 308 amino acid residues, the 
sequence that codes for the catalytic domain. The GFP sequence had a point mutation to 
prevent the dimerization of GFP, by changing ~ e u ~ "  to a Monomeric EGFP 
(inEGFP) tagged CaMK-I1 sequences were amplified through PCR, using Hi-Fidelity 
Platinum Tag polymerase (Invitrogen). The amplification was primed at the C-terminal 
end of the gene, with a primer containg a BamHI cut site. The a and P were specifically 
primed by, CCCGGATCCTTACTGGGGCAGGACGGAGG and 
CCCGGATCCTCACTGCAGCGGGGCCACA, respectively. The three 6 constructs 
were primed with a y specific primer because each was a chimera with the y association 
domain with the primer CCCGGATCCTCACTGCAGCGGTGCGGCA. The N-terminal 
side of the GFP sequence of all five constructs was targeted by a primer with a KpnI cut 
site, CGCGGTACCATGGTGAGCAAGGGCGAGGAG. The PCR products were 
ligated into the pCDNA-3.1' vector, which had previously had the FLAG-2AB sequence 
cloned into it at the Hind111 site of its multiple cloning region (the plasmid was provided 
courtesy of Dr. Mark Mayhew at the University of Virginia). Five vectors were created; 
FLAGImGaWT, FLAGImGPWT, FLAG/mGGcWT, FLAG/mGGEWT, and FLAG/mGGE- 
C-terminal. The constitutively active FLAG construct (FLAG/mGGECon) was generated 
by site directed mutagenesis, substituting ~s~~~~ for ~ h r ~ ~ ~  of a FLAG/mGGEWT 
construct (GCATCGTCAGGAGGACGTGGAGTGTTTGCG) using Pfu Ultra high 
fidelity long read polymerase (Stratagene, LaJolla, CA). The plasmids were confirmed 
by restriction digest, immunoblots, CaMK-I1 activity assays, and DNA sequencing and 
showed tliat all five had been accurately constructed. 
FLAG-transfection. 
Approximately 80% confluent cells in 1 OOmm tissue culture dishes were 
transfected with 4 pg of FLAG plasmid and diluted with 8pg of p ~ ~ - ~ ~ +  using 
lipofectamine 2000 in Optim-MEM and 3% FBS (Invitrogen, Carlsbad, CA). Four hours 
post-transfection, cells were either refed with DMEM/lO%FBS or trypsinized and 
replated at 50% of their original confluence in DMEM/lO%FBS. Cells were harvested 
18-24 hours later as described above. 
FLAG Immunoprecipitations. 
1 mg of total protein from FLAG-transfected cell lysate was precleared with 50pL 
of mouse IgG conjugated to agarose at lmg/mL (Sigma, St. Louis, MO) overniglit at 4OC 
with rocking. The supernatant was then combined with 50uL M2 agarose anti-FLAG at 
O.Gmg/mL (Sigma) and incubated for 2-5 hours with rocking at 4OC. The beads were 
then washed twice with 0.5mL HBIprotease and phosphatase inhibitors/O.l%NP-40, 
followed by one wash with 0.5 mL of sterile 30mM Tris pH 7.4. Immunoprecipitated 
proteins were then eluted twice with 100 pL sterile 30mM Tris and 0.2 mg/mL FLAG- 
elution peptide (Sigma) for 15 minutes on ice. Samples were immediately frozen until 
MSMS analysis. 
Tandem Mass Spectrometry. 
Samples for MS/MS were prepared by reduction and alkylation. A portion of the 
FLAG eluent was incubated in 10 mM DTT for 1 hour at 37OC to reduce the sample then 
alkylated, with 5 pM Iodoacetic acid for 30 minutes at room temperature in the dark and 
then again with DTT to quench the Iodoacetic acid. The sample was then digested with 
Endoproteinase Lys-C, which cleaves peptides on the C-terminal side of Lys residues, 
and Trypsin, which cleaves at the C-terminal side of Arg and Lys residues, at 200 pg/mL 
for one hour at 37OC. The mass spectral analysis was performed on a Finnigan LTQ- 
FTMS machine and analyzed using tlie accompanying software and scored using the 
SEQUEST approach (ThermoElectron Corp, San Jose, CA). These protocols are the 
standard teclmiques used at the University of Virginia Mass Spectrometry Facility and 
can be found in greater detail at: 
Immunoprecipitations. 
100 pg of NIH 3T3 lysate protein was incubated with 1 pg of primary antibody 
overnight at 4OC. 1.5 pg biotinyalated secondary antibodies were added to the solution 
and incubated for 2 to 5 hours at 4OC. They were then incubated with 30 pL of pre- 
washed streptavidin-Magnesphere (Promega, Madison WI) or Protein-G Dynabead 
(Dynal/Invitrogen, Carlsbad, CA) paramagnetic beads for 1-2 hours at 4OC with rocking. 
The Immunoprecipitates were then washed 3 times with 500 pL cold HB in a magnetic 
separation stand and were then resuspended in 20 pL of HB. Immunoprecipitates for 
CaMK-I1 activity assays were frozen until use or were combined with SDS sample buffer 
containing 30 mM DTT and boiled for SDS-PAGE. 
Immunoblots. 
Immunoprecipitates were separated on 4-15% or 10% SDS-PAGE gels using the 
Mini-Protean I1 gel electrophoresis system (Bio-Rad, Hercules CA). Proteins were 
transferred to 0.45 pm nitrocellulose sheets for 1 h at lOOV and blocked with Tris 
Buffered Saline, 0.01% Tris-20, and Sodium Azide (TBSTA), containing 5% BSA and 
2% pre-immune serum of the secondary antibody host for 1 hour. Blots were then 
incubated overnight with primary antibodies at 1 pg/ml in 2% BSAITBSTA. Blots were 
washed three times with TBSTA and incubated for 2-5 hours with alkaline phosphatase- 
conjugated secondary IgG at 2 pglml in 2% BSAJTBSTA. The blots were washed once in 
O.1M NaCl and 5mM MgC12 at pH 9.4 and developed with 0.25 mg/niL of both nitro blue 
tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP). 
Total Protein Stain. 
Saniples to be stained for total protein were separated on 10% polyacrylamide 
gels. The gel was then fixed for 30 minutes at room temperature in 50% methanol and 
10% acetic acid. It was then incubated overnight at room temperature in undiluted 
SYPRO Ruby protein gel stain (Molecular ProbesIInvitrogen, Carlsbad, CA) in an 
opaque developing tray. The gel was washed twice for thirty minutes in a 10% methanol 
and 7% acetic acid solution then rinsed twice with dH20 and visualized on a W- 
traiisilluniinator (UVP, Upland California). 
Calmodulin Overlay. 
The samples for calmodulin overlays were transferred to nitrocellulose, and then 
blocked with TBS containing 0.1% Tween-20,2rnM CaC12 for 30 minutes at room 
temperature. Blots were then placed in TBSTAl2mM CaC12 with 1 pg/mL of biotinylated 
calmodulin (Calbiochem, San Diego, CA) and incubated overnight at room temperature. 
The blots were then washed three times in TBSl2mM CaC12/0.1% Tween-20 for 10 
minutes at room temperature. Blots were then transferred to TBSl2mM CaC12/0. 1% 
Tween-20 and 2pgImL alkaline phosphatase-conjugated streptavidin (Jackson 
Immunology Labs, West Grove, PA) and incubated at room temperature for 1-2 hours. 
All blots were washed three times as above and developed in 0.25 mg1mL of NBT and 
BCIP each in O.1M NaCl and 5niM MgC12 at pH 9.4. 
CaMK-I1 Activity Assays. 
Total CaMK-I1 activity was assessed by measuring phosphate incorporation into 
an artificial substrate. The kinase reactions were carried out in a solution of 20 mM 
HEPES (pH 7.4), 0.1 mM dithiothreitol, 15 mM magnesium acetate, 20 mM P- 
glycerophosphate, 0.5 pM PKA inhibitor peptide, 0.1 pM okadaic acid, 40 pM sodium 
orthovanadate, 0.5 mCi [ y - 3 2 ~ - ~ ~ ~ ] ,  35 pM autocamtide-2 (peptide substrate), 1 pM 
calmodulin, 1 mM EGTA, and either none or 3 mM ca2+. The reaction ran for 10 minutes 
at 30°C, then 20 pl was pipetted onto P81 phosphocellulose paper squares that were air 
dried for 1 mi11 and washed five times in 500 mL 1% phosphoric acid. The samples were 
quantitated by Cerenkhov counting in a Beckman LS6000IC scintillation counter. The 
sequence of autocamtide-2 is KKALRRQETVDAL and the assay conditions were 
previously optimized for detection of CaMK-I1 activity ( Tombes et al., 1999; Tombes et 
al., 1995). 
Imunolocalization. 
Cells were grown on glass cover slips that had been preincubated with 1 pg/mL of 
fibronectin and then fixed in methanol at - 2 0 ' ~  for 3 min. Fixed cells were blocked 
overnight at 4OC in TBSTA containing 5% BSA and 2% appropriate pre-immune serum. 
Cells were then incubated for 1 hour at 37OC with 0.2 yg/mL of primary antibody in 
TBSTA/2% BSA in a humidified chamber solution then washed in TBSTA three times 
for 5 minutes. The cover slips were then incubated with 1 pg/mL of Texas Red 
conjugated secondary antibody in TBSTA/2% BSA for 30 minutes at 37OC in a 
humidified chamber and washed as described above. They were then mounted onto glass 
slides and stored until imaged. 
Imaging. 
All phase contrast and fluorescent images were taken 011 an Olympus IX-70 
inverted microscope using a 12-bit camera (Olympus, Melville, NY). Fluorescent images 
were taken with two second exposures using a 595 nm dichroic long pass filter (Chroma, 
Rockingham, VT) illuminated by a mercury arc lamp. The images were processed using 
Olympus Microsuite version Five. 
Antibodies. 
The mouse anti-flightless-I antibody was a purified moi~oclonal, mouse IgG, at 
ImgImL, from Covance, Berkeley, CA. The mouse anti-p CaMK-I1 primary antibody 
was obtained from ZymedIInvitrogen Carlsbad, CA. The goat anti-6 CaMK-11, rabbit 
anti-GFP and goat anti-Tropomodulin-3 were purchased from Santa Cruz 
Biotechnnology, Santa Cruz CA. The monoclonal mouse anti-cofilin and anti-integrin 
was bought from BD Biosciences/Pharmingen in Sane Diego, CA. The goat anti-mouse, 
texas red conjugated, donkey anti-mouse conjugated to biotin, donkey anti-goat biotin 
conjugated, and biotinylated donkey anti-rabbit secondary antibodies were all purchased 
from Jackson Imunological Laboratories, West Grove, PA. 
Results 
Identification of CaMK-I1 Binding Partners. 
The first half of this study was to identify protein binding partners of CaMK-I1 
using MSNS.  Five FLAG-tagged CaMK-I1 (a, PE, i?iC, tiE, and i?iE C-terminal) constructs 
were transfected into NIH 3T3 cells and one into P19 neurons. The bait DNA was 
diluted 1:3 with an empty pBlueScript vector, which kept the transfection efficiency high 
but allowed for the tagged CaMK-I1 to mix with the endogenous population. This helped 
to correct for the artificial nature of the experimental conditions. 
Four hours post-transfection the cells were sub-cultured to ensure that the cells 
were motile and actively progressing through the cell cycle. They were harvested 16-24 
hours later. The tagged proteins were isolated with antibodies against the FLAG-tag and 
eluted two times using a FLAG-elution peptide. The FLAG IP and elution process 
effectively cleared non-specifically bound proteins from the lysates during the first 
elution, which was confirmed by total protein stains and GFP Western blots (Figures 1A 
and B). 
The eluents of the IPS were then analyzed by MSIMS and yielded a number of 
potential binding partners. In total eleven MSIMS experiments were conducted. The 
first was with the FLAG/mGGE-C-terminal construct, which lacked the catalytic domain 
and was carried out in transfected P19 neurons. In this experiment CaM and CaMK-I1 
were detected, which served as an internal control supporting the validity of the 
approach. Additionally several previously identified CaMK-I1 binding partners were 
detected including btubulin and P- and y-actin fbrther corroborating the legitimacy of 
the data (Easley, et al., 2006). Experiments two and three were duplicate experiments of 
each other with FLAG/mGPEWT. The results from the experiments were nearly 
identical, further substantiating the results as authentic. The fourth, fifth, and sixth 
experiments were performed in the same fashion as the initial three, except with 
FLAGImG ScWT, FLAGImG FEWT, and FLAGImGDaWT, respectively. The PE, SC and 
SE isozymes were selected because they are all endogenously expressed in NIH 3T3 cells. 
a CaMK-I1 is not typically present, but it represented an effective point of comparison, as 
did SE-C-terminal because it is effectively catalytically inactive which is why they were 
chosen for the screen. 
The results from these six experiments yielded many previously unidentified 
binding partners including a number of actin capping and binding partners, such as Fli-I 
(and two of its associated proteins LRRFIP-I and -II), tropomodulin-3, and cofilin. 
These actin capping proteins were of particular interest because of the documented but 
not specifically characterized role of CaMK-I1 in cytoskeletal regulation. Other proteins 
of interest identified in the screen included myosin heavy and light chain and vimentin 
(table I). 
Four additional MSMS experiments were performed using less stringent 
harvesting and immunoprecipitating conditions. Low salt HB, which was similar to the 
composition of standard HB except for the lack of 80 mM P-glycerol phosphate, was 
used to reduce the ionic strength of the buffer. FLAG/ FE-C-terminal and 
FLAG/mGSEWT were transfected into NIH 3T3 cells and harvested under both normal 
and low salt coiiditions and analyzed by MSMS. Although it was suspected that 
additional proteins could be identified because their interaction with CaMK-I1 had been 
disrupted by the stringency of the preceding experiments, no additional candidates were 
detected by this method. The final experiment was a negative control experiment using 
FLAGIGFP with no cDNA cloned into it and harvested under the standard conditions. 
The results from this experiments were subtracted from the data to correct for proteins 
that may have non-specifically bound either GFP or the FLAG-tag. 
A large volume of data was generated from the various MSIMS experiments. It 
was not possible to initially pursue all of the potential binding partners identified in the 
screen. It was necessary to select either one or several specific targets to characterize 
experimentally. Additionally, several pieces of the data were dismissed as artifacts of the 
experimental conditions. These included peptides corresponding to human keratins that 
were detected in all of the screens because they were assumed to be contamination that 
was introduced during the preparation of the samples. Other results were generated by 
only one or two peptides and were given a very low score of legitimacy and were also 
dismissed. Certain results, such as various immunoglobins and several stress response 
proteins were disregarded as false positives. A list of all of the identified proteins can be 
found at littp://www.cellmigration.org/resource/discoveryl#binding. 
A review of the current literature made Fli-I the first choice for detailed analysis 
from our screen. The interaction of CaMK-I1 and Fli-I had the most potential for further 
analysis. The commercial availability of a quality antibody against this protein helped to 
establish it as the subsequent focus of the study. 
Interaction of Endogenous Fli-I and CaMK-11. 
The identification of Fli-I as a potential CaMK-I1 binding partner from our 
MSIMS screen was in an artificial system due to transfection and the over expression of 
CaMK-11. It was essential to confirm this as a legitimate interaction and not an artifact of 
the experimental conditions. This was done by using reciprocal immunoprecipitations of 
untreated NIH 3T3 lysates. 
When P and 6 CaMK-I1 antibodies were used to immunoprecipitate endogellous 
proteins it was possible to successfully probe for Fli-I on Western immunoblots. Both 
IPS yielded a band in the 145kDa region which corresponds to the MI of Fli-I (Figure 
3A). Although a CaMK-I1 was used in the M S N S  screen it is not normally expressed in 
NIH 3T3 cells, so it was not possible to test this endogenous interaction. 
Conversely, Fli-I was immunoprecipitated from untreated 3T3 lysates. The 
immunoprecipitate was transferred and probed with CaM to screen for CaM binding 
proteins. For this purpose this approach is more effective than a traditional immunoblot. 
Many CaMK-I1 isozymes have a similar MI as IgG heavy chain and so they migrate at 
similar rates during SDS-PAGE experiments. It is not possible to discern whether the 
bands that are detected because the secondary antibody is bound to the IgG heavy chain 
or to CaMK-11. Using CaM conjugated to biotin makes it possible to eliminate off-target 
interactions of the secondary antibody and to screen only for CaM binding proteins. As 
was expected the CaM overlay experiment revealed bands in the 50-60 kDa region, 
which corresponds to CaMK-I1 isozyme migration patterns (Figure 2B). 
Additionally we used Fli-I IPS to screen for associated CaMK-I1 with CaMK-I1 
enzymatic activity assays. Using autocamtide-2, an artificial CaMK-I1 substrate it was 
possible to detect CaMK-I1 enzymatic activity by measuring the incorporation of 3 2 ~  
from Fli-I IPS into the peptide. Kinase reactions run with this IP showed -that almost 20% 
of the CaMK-I1 activity detected in whole cell lysates could be recovered in the IP. This 
is in comparison to immunoprecipitation with an anti-integrin antibody, which is a 
protein known to not bind CaMK-11, in which only 1% of the total cellular activity could 
be recovered. This experiment confirmed the interaction enymatically (Figure 3C). 
CaMK-I1 Activity Dependent Interaction with FIi-I. 
The next question I raised explored the nature of the CaMK-11-Fli-I interaction in 
relation to CaMK-I1 activity. For this, NIH 3T3 cells were transfected with FLAG/mGGE 
constructs and the level of CaMK-I1 activity was varied. Several approaches were 
utilized to vary CaMK-I1 activity; one was to use a constit~~tively active CaMK-I1 mutant 
(FLAG/mG&Con), which had an ~s~~~~ point mutant at ~ h r ~ " ,  the autophosphorylation 
site. The other cells were transfected with wild type constructs (FLAG/mGGEWT). To 
inhibit CaMK-I1 we used two different drugs, KN-93 a reversible CaM antagonist which 
prevents CaM binding and hence CaMK-I1 activation and a myristoylated autoinhibitory 
peptide (rnAIP), a membrane permeant peptide which mimics the autoinhibitory domain 
of CaMK-11, inactivating CaMK-11. The lysates of the transfected cells were 
immunoprecipitated with an antibody against the GFP tag and then probed with Fli-I 
antibodies. The constitutively active CaMK-I1 co-precipitated a much greater amount of 
Fli-I than did the untreated wild-type CaMK-I1 suggesting that the increased level of 
activity resulted in a greater degree of association. Conversely, the KN-93 and mAIP 
inhibited lysates immunoprecipitated less Fli-I than the wild type sample and 
considerably less than the constitutively active sample (figure 4A). Interestingly, when 
the samples were immunoblotted for GFP as a control, the FLAG/mGGECon was 
expressed at a lower level that then other samples (not shown). Additionally, when the 
total CaMK-I1 activity in the samples was measured as a means of determining the 
relative concentration of CaMK-I1 it was seen that the inhibited C a m - I 1  samples were 
expressed at 5 times the levels of the wild type and twenty times the level of the 
constitutively active sample (figure 4B). This is consistent with what is normally seen; 
the constitutively active CaMK-I1 is expressed at lower levels, although the exact cause 
of this phenomenon is unknown. The percent of CaMK-I1 autonomy in the samples was 
determined enzymatically. It revealed that over 50% of the CaMK-I1 in the constitutively 
active sample was autonomous as compared to less than 20% in the untreated sample and 
no more than 2% in the inhibited samples (figure 4C). These three results create an 
interesting picture in which the CaMK-I1 in the constitutively active sample, although 
expressed at a lower level bound more Fli-I than did the inhibited samples, which were 
expressed at greater levels. The activation state of CaMK-I1 dictates whether it is capable 
of binding Fli-I. 
Localization of Fli-I in NIH 3T3 Cells. 
The confirmation of the interaction between CaMK-I1 and Fli-I in untransfected 
cells and the dose dependent interaction in transfected cells raised questions about the 
patterns of Fli-I localization in vivo. This was addressed by immunohistochemistry using 
Fli-I antibodies. NIH 3T3 cells were grown on glass coverslips then fixed in methanol. 
Methanol rather than formaldehyde was the fixative used because the latter caused a loss 
of Fli-I antigenicity. 
We observed that in untreated cells there are several distinct localization patterns. 
Fli-I is capable of nuclear translocation under certain conditions and was found in many 
cells (Figure 5A), but in many of the cells in the same sample it localized outside of the 
nucleus. This is consistent with published results on Fli-I localization patterns. It is 
believed that when Fli-I is located in the cytosol it is associating with actin based 
structures, such as those found at the leading edge of motile cells and in perinuclear 
regions (Figures 4B and C). The patterns observed in the experiments are consistent with 
the current models of Fli-I behavior. Fli-I is known to act as a transcriptional co-activator 
and nuclear receptor binding protein, both of which may be coupled to its nuclear 
translocation, but it is believed that this translocation occurs primarily when cells are cell- 
cycle arrested or non-motile. Although it was observed that Fli-I could assume one of 
several localization patterns, groups of neighboring cells seemed to generally exhibit 
similar patterns, which is likely the result of the cells responding to cues in their 
microenvironment which influence their behavior. 
Fli-I Localizes to the Nucleus in Arrested Cells. 
Since within a single culture Fli-I could assume one of several localization 
patterns it was a challenge to create a consistent trend throughout each experiment. 
Based on published findings that Fli-I is sequestered in the nucleus of arrested cells, it 
seemed logical that arresting the cells via serum deprivation would syiichronize the entire 
population of cells in each experiment. With this treatment it was possible to induce 
arrest throughout the culture, which caused the cells to display only nuclear localization 
patterns (Figure 6B and C). This induced arrest allowed more direct control of the cells' 
progression through the cell cycle and their migratory state. It was also realized that 
greater regulation could be established if the cells were plated on glass coverslips that had 
been pre-incubated with fibronectin (FN). This allowed the cells to attach at a faster rate 
so it was possible to more directly regulate the cell density. The density of the culture 
was important because the cells are inhibited by contact and will readily arrest when they 
touch neighboring cell and cause Fli-I to translocate to the nucleus (Figure 6D). 
Fli-I Does Not Localize to the Nucleus in Serum Stimulated Cells. 
It was necessary to accurately characterize the behavior of Fli-I under various 
conditions before being able to assess the effects of CaMK-I1 activity on its localization. 
Serum starving cells overnight after they had been plated on FN coated coverslips was 
adopted as the standard practice for all of the Fli-I localization experiments. Once the 
cells had been arrested overnight, they were then released by stimulation with 10% FBS 
containing medium. Cells that were fixed at various time points post-stin~ulation showed 
an increasing return of Fli-I to the leading edges of the cells. Six hours after the cells 
were stimulated, Fli-I could be seen associating with actin arches throughout the cells 
(Figure 7C). It seemed as although by 15- 16 hours the majority of the cell's Fli-I is 
extra-nuclear, with some being localized in the perinuclear region and much of it 
localized to ruffles at the cell's edge (Figure 7D). Although it is possible to induce 
exportation of Fli-I from the nucleus of arrested cells by stimulating, we still observed 
that once the cells begin to contact one another it induced Fli-1's return to the nucleus, 
meaning that the contact induced arrest is able to overcome the effects caused by the 
serum stimulation. 
CaMK-I1 Inhibition Also Targets Fli-I to the Nucleus. 
It was apparent from the initial localization experiments that Fli-I is a very 
dynamic molecule and that its localization is closely coupled to the activity state of the 
cell. Once protocols had been established for regulating Fli-1's behavior as consistently 
as possible, it was feasible to determine the effects of CaMK-I1 activity on its 
localization. The first goal was to limit CaMK-I1 activity and assess the effects on Fli-I 
localization. This was accomplished with the CaMK-I1 inhibitor KN-93. The cells were 
plated in the same fashion as they were in the serum dependence experiments, but 10 pM 
KN-93 was added to the media at the same time point that serum free medium has 
previously been added. In a very similar manner to serum starvation, KN-93 caused Fli-I 
to shuttle into the nucleus. This effect was observed in a time dependent fashion with the 
the effect being seen within four liours (figure 8B), continuing to translocate in at 12 
hours (figure 8C), and being all in by 18 hours (figure 8D). A similar experiment was 
performed using 10 pM mAIP as the CaMK-I1 inhibiting agent. This treatment resulted 
in an effect very similar to the KN-93 dependent inhibition. The mAIP caused Fli-I to 
exit the cytoplasm of the cells and migrate to the nucleus within 90 minutes (Figure 9B) 
and being non-cytosloic by three hours (figure 9C). The mAIP had maximal effect 
within three hours, which was much faster than what was seen with the KN-93 treatment, 
but this is likely due to the differences in the two drugs' specific modes of action. It was 
very interesting to be able to induce Fli-I localization patterns similar to those seen in 
arrested cells by inhibiting CaMK-11. This complemented the Fli-I Western blot of the 
various CaMK-I1 activity treatments in an in vivo model. 
Fli-I Leaves the Nucleus in Artificially Activated CaMK-I1 Cells. 
Once it was clear that Fli-I could be sequestered to the nucleus by restricting 
CaMK-I1 activity, I wondered if I could reverse this localization by artificially activating 
CaMK-11. The first thought was to transfect cells with a constitutively active CaMK-I1 
and localize Fli-I, which was the most straight forward approach to forcing Fli-I to return 
to the cytosol. Although we were able to successfully transfect the cells, there was no 
noticeable effect on Fli-I localization. It was observed however, that cells that had been 
transfected with the constitutively active construct had arrested, which resulted in Fli-I 
assuming nuclear localization. It was unclear if this effect was the result of the CaMK-I1 
activity or another pathway, but it was apparent that it would not be an effective effective 
for demonstrating the effect of C a m - I 1  activity of Fli-I localization. The next method 
employed was to artificially activate endogenous CaMK-I1 by treating cells with the ca2+ 
ionophore ionomycin. Ionomycin causes ca2' influx into cells, which results in CaMK-I1 
activation. The cells were maintained in serum free media, which we had previously 
shown to cause Fli-I to transport to the nucleus. Although the culture was maintained in 
the absence of serum, treatment with ionomycin caused Fli-I to exit the nucleus and 
associate with stress fibers and in the perinuclear region of the cell. The transport of Fli-I 
out of the nucleus occurred in a time dependent fashion, with the effects becoming 
noticeable between 3 to 6 hours post-treatment (figure IOB) and seemingly complete by 
16 hours (figure 10C) after the drug was added. When compared to the effects seen when 
cells are treated with serum free media, the translocation of Fli-I in response to ca2+ 
establishes a clear link between it and cellular ca2+ and when combined with the results 
of CaMK-I1 inhibition it confirms that CaMK-I1 serves as a regulator of Fli-I. 
Discussion 
The role that CaMK-I1 plays in essential cellular functions is often 
underappreciated. Its high level of evolutionary conservation, broad patterns of 
expression, and unique regulation exemplify the essential role of CaMK-I1 in cellular 
function (Tombes et al., 2003). To identify new functions of the protein it is necessary to 
use open minded approaches. An unbiased process for achieving this goal is to discover 
new binding partners in the hope that they could be correlated to unknown functions. 
The MSIMS used in study was ideal for this type of screen. 
The MSIMS screen is an excellent tool for the identification of binding partners, 
although the artificial nature of the system made it susceptible to erroneous results. 
Although false positive results were a possibility the identification of both CaM and 
CaMK-I1 in the screen validated the methodology. Although the data appeared genuine it 
was necessary to confirm the endogenous interaction. In particular Fli-I was a fascinating 
result and it had a commercially available high quality antibody against it, so it was the 
logical choice for study. Several additional targets were considered including 
tropomodulin-3 and cofilin, but the antibodies purchased against these proteins could not 
be confirmed as efficient in endogenous systems so they were not pursued further (data 
not shown). 
Fli-I is a member of the Gelsolin Related Actin Binding Partner (GRABP) family. 
It is a 145 kDa protein that is highly conserved and expressed in all metazoans. The C- 
terminal side of Fli-I is a Gelsolin-like domain which gives Fli-I its actin binding and 
capping ability and the N-terminal half is a Leucine Rich Repeat (LRR), a conserved 
domain known to be involved in protein protein interactions (Archer et al., 2005; 
Campbell et al., 2000). The gene was identified in Drosophila melanogaster mutants that 
did not develop the ability to fly. It was discovered that they were lieterozygous mutants 
of the gene located on the 19F region of the X-chromosome and that the loss of flight was 
the result of a failure to successfully cross bridge the actin filaments of in-direct flight 
muscles. Homozygous Fli-I null mutants are embryonic lethal, which is a more severe 
phenotype than villin or double Cap-G and Gelsolin knockouts, both GRABPs family 
members. The lethality of the knockouts and the high degree of genetic conservation are 
illustrative of the importance of this niolecule (Lee et al., 2004; Straub et al., 1996; 
Campbell et al., 2002). 
Fli-I possesses a variety of functions. It is known to have actin binding function 
and to associate with actin based structures during development and cell motility (Davy 
et al., 2000; Davy et al., 2001). Additionally, Fli-I fuiictions as a transcriptional co- 
activator through its interactions with nuclear receptor based complexes as identified 
during yeast-two hybrid screens (Archer et al., 2004; Lee et al., 2004; Liu and Yin, 1998; 
Archer et al., 2005). This broad range of functions is apparent by the intra- and 
extranuclear localization patterns it exhibits. 
Fli-I lacks a domain that would allow it to respond to ca2+, which is something 
that the other members of the GRABP family possess (Fong and de Couet, 1999). ca2+ 
based signaling is fundamental to many cellular processes including regulation of 
cytoskeletal dynamics. Fli-I is a critical component of this process and although it is not 
directly regulated by ca2+ transients it could be controlled by them through its interaction 
with CaMK-11. It has been speculated that Fli-I could serve as an intermediate between 
ca2+ based signal transduction pathways and the regulation of cytoskeletal dynamics 
(Claudianos and Campbell, 1995; Davy et al., 2000; Davy et al., 2001). 
The Fli-I antibody was specific in immunoblots of endogenous 3T3 and P19 
lysates. This made it possible to probe for its presence in CaMK-I1 IPS and also to screen 
for CaM-I1 in Fli-I IPS. The CaMK-I1 IPS contained Fli-I on Immunoblots, which 
verified the interaction and was supported by the detection of CaMK-I1 in Fli-I IPS, both 
immunologically and enzymatically. The complementary nature of these experiments 
which were performed on native proteins corrected for the synthetic nature of the initial 
screens. The reciprocal verification of the interaction confirmed the legitimacy of the 
MS/MS result. 
The authenticity of the interaction was apparent and seemed to have potential as 
molecularly significant, but nothing was known of the nature of the interaction. All of 
the MSMS experiments contained Fli-I so it was not possible to discern any information 
from the variations in the screens. Since CaM-I1 fbnction is closely coupled to its 
activation state, it was logical to wonder if that had an effect on the association. 
Transfection of NIH 3T3 cells with GFP-tagged constructs offered several 
advantages in charactering the CaMK-11-Fli-I association. It made it possible to use a 
constitutively active variant and to immunoprecipitate against the GFP-tag whicli is more 
specific than antibodies against CaMK-11. The inhibited samples were also transfected to 
maintain consistency between the samples. These experiments illustrated the activity 
dependence of the interaction. The increased quantity of Fli-I bound to constitutively 
active CaMK-I1 and decreased association as a result of lowered activity suggest that the 
nature of the interaction makes it possible to determine the activation state of CaMK-11. 
Little is currently known about the domains that are facilitating the interaction of 
these proteins, but it is clear that the activation state of CaMK-I1 somehow regulates the 
interaction. A likely possibility is that upon CaMK-I1 activation a Fli-I binding site is 
either created or exposed. Recent work on the crystal structure of CaMK-I1 suggests that 
activation causes the core domain of the CaMK-I1 holoenzyme to expand, which could 
expose a Fli-I binding site (GaeiZner et al., 2004; Rosenberg et al., 2005). Fli-I possesses 
a traditional nuclear localization signal (PKKKRKV). It is possible that when Fli-I is 
b o ~ ~ n d  to CaMK-I1 the sequence is obstructed, preventing the formation of a nuclear 
import complex. Although CaMK-I1 activation occludes Fli-I from the nucleus, the 
isozymes of CaMK-I1 examined in this study are non-nuclear, so they can not enter the 
nucleus to retrieve Fli-I. An explanation is that CaMK-I1 is not responsible for Fli-1's 
export from the nucleus, but maintains its presence in the cytosol when it is active. 
Fli-I is very active in its localization. Since it becomes sequestered to the nucleus 
of arrested cells, it made sense that the translocation could be correlated to its association 
with CaMK-11. Localizing Fli-I in control cultures proved to be a challenging task. To 
accomplish this it was necessary to synchronize the progression of the cell's cycles and to 
closely control their density. This was achieved by arresting and releasing them and 
culturing them on FN. Much information about the nature of their binding became 
apparent when the localization patterns of Fli-I were characterized during various cell 
activity states and comparing them to multiple levels of CaMK-I1 activity. In arrested 
cells Fli-I is found primarily in the nucleus and although some can be detected outside the 
nucleus, it is non-specifically present. The location of Fli-I is similar in arrested cells and 
CaMK-I1 inhibited cells suggesting that under naturally occurring conditions their 
interaction may be somehow correlated to the cell cycle and to cytoskeletal dynamics. 
It was asked if Fli-I was not only a CaMK-I1 binding partner, but also a substrate. 
Phosphorylation could represent an additional level of regulation in addition to the 
activity dependent binding between the two proteins. There are five potential CaMK-I1 
consensus sequences in Fli-I, but the structure of the protein is unknown so they may not 
actually be phosphorylatable. This was tested by partially purifying CaMK-I1 and 
combining it with Fli-I IPS in the presence of [ y - 3 2 ~ - ~ ~ ~ ] .  The assay was crude in 
nature, but the initial autoradiographs indicate that Fli-I is not a CaMK-I1 substrate (data 
not shown). Although the reactants were not completely pure and the results can not be 
considered definitive, they are still convincing. Binding that is dependent on 
autophosphorylation is a seen throughout the cell, such as receptor tyrosine kinases, 
which a~~tophosphorylate when they bind ligands to mediate their signal transduction by 
only binding signaling proteins when they are phosphorylated. It is possible that CaMK- 
I1 binds Fli-I through a similar mechanism. 
A clue to the function of the interaction is another binding partner identified ill the 
screen, the protein known as leucine rich repeat region of Fli-I interacting protein I1 
(LRRFIP2). Little had been known of the function of LRRFJP2 other than its association 
with Fli-I, until recently when it was shown to be a positive regulator of the Wnt 
signaling pathway in yeast two-hybrid screens (Liu et al., 2005; Liu et al., 1998). It was 
shown that LRRFJP2 is a positive effector of the canonical Wnt pathway through an 
interaction with Disheveled (Dvl). When a Wnt ligand binds to its receptor, Frizzled 
(Fz), Dvl is activated and inhibits GSK-3P, releasing kcatenin, which then translocates 
to the nucleus and interacts with TCF to function as a transcription factor. 
If Fli-I is localized in the nucleus, LRRFIP2 can not interact with Dvl to up 
regulate kcatenin mediated transcription. Since Fli-I is extra-nuclear in a manner 
proportional to CaMK-I1 activity, Wnt signal transduction would be elevated at times of 
high activity. This model suggests that extracellular signaling has regulators inside of the 
cell, which would mean that the pathway has increased sensitivity to a variety of stimuli. 
In transformed cells CaMK-I1 expression is down regulated (Tombes et al., 1999), 
meaning that extracellular signals which are transduced by the canonical Wnt pathway 
are not efficiently relayed, which could contribute to the carcinogenic characteristics 
exhibited by these cells. This could be a previously undescribed regulatory pathway that 
needs to be fi~rther characterized. 
A number of additional experiments are necessary to more specifically define the 
nature of the interaction. They include: 
Adding the GFP tag to Fli-I 
Fluorescently tagging Fli-I would make it possible to characterize its 
movement in living cells and to analyze its kinetics into and out of the 
nucleus under different conditions 
Colocalizing CaMK-I1 and Fli-I 
The localization of Fli-I can be complimented by showing the position of 
CaMK-I1 and Fli-I at the same time under the various experinlental 
conditions that Fli-I alone was localized during. This could be done by 
imaging each protein in different fluorescent channels. 
Domain Mapping of the CaMK-11-Fli-I interaction 
To further understand the properties of the interaction it is essential to 
know where they binding is occurring. This can be done by using deletion 
constructs, which create truncated proteins and deterniine which domains 
are essential for binding. This could be followed up by using point 
mutants to define the required amino acid residues to facilitate binding. 
In vitro translation and direct binding assay 
Using reticilolysate it is possible to translate proteins in vitro and test for 
their interaction. mRNA made from CaMK-I1 and Fli-I could be 
translated and the interaction could be confirmed. This would eliminate 
any question of whether or not the association of Fli-I and CaMK-I1 is 
direct or indirect. There are commercially available kits for this type of 
assay which makes this a practical and worthwhile experiment. 
Biochemical Characterization of the CaMK-11-Fli-I interaction 
Currently nothing is known of the biochen~ical aspects of the interaction 
and will need to be defined. This will include studying the kinetics of 
the Fli-I translocation, its rate of turnover, the binding affinity of the two 
proteins, and identifying which growth factors are essential to keep Fli-I in 
the cytosol. These experiments will reveal in greater detail the already 
confirmed interactioii and offer insight to its intracellular functions. 
Gene expression effected by the CaMK-11-Fli-I interactioii 
Using CaMK-I1 inhibitors to minimize its activity and RNAi to lower Fli-I 
expression gene expression patterns can be characterized using DNA 
microarray analysis. Genes that are down regulated when both CaMK-I1 
is inhibited and Fli-I expression is minimized could potentially be 
dependent on the interaction. 
The effects of CaMK-I1 oil Wnt pathway components 
Since it is possible that through its interaction with Fli-I and 
LRRFIP2 that CaMK-I1 could be effecting Wnt based transcription it will 
be necessary to examine what is happening to components in the pathway. 
This can be done immunologically to look at the phosphorylation state of 
GSK-3P or for the presence of p-catenin, for example. 
Whole organism studies 
It is important to also characterize the effects of this interaction in a whole 
organism. Since both proteins are developmentally essential a good 
system for studying their roles during development would be the zebra 
fish, Danio rerio. 
These experiments will make if possible to further describe the CaMK-I1 and Fli-I 
interaction. This work is the first description of what has the potential to be a new 
intracellular regulatory pathway. Both of these proteins are ubiquitously expressed and 
highly conserved throughout all metazoans. This is reflective of their cellular importance 
and means that their interaction could be quite ancient. The complexity with which each 
is regulated is profo~~nd, but is even more intricate when they cooperate. The 
identification of Fli-I and CaMK-I1 by MSIMS is exciting not only because of its cellular 
significance but because it is representative of a new class of biochemical approaches 
which will make it possible to characterize the cross talk that exists between well 
established cellular pathways. 
Table 1. MSIMS Results Table. The Names, NCBI protein accession numbers, and total 
number of peptides detected of tlie proteins identified as potential CaMK-I1 binding 
partners using MS/MS. The total number of peptides is the number of peptides that were 
analyzed and analyzed by SEQUEST to determine the legitimacy of the result. 
FLAG mEGFP Catalytic Variablc issociation 
731-811 
Figure 1. Linear FLAG/GFP-Cam-II map. The FLAG-tag was hsed to the N-terminal side 
of the GFP tag and is 8 residues long. The GFP-tag is 245 amino acids long and is located on 
the N-terminal side of CaMK-11. The catalytic domain of CaMK-IT is just over 250 amino 
acids long and is adjacent to the regulatory domains, which is 30 residues in length. The 
variable domain differnces in size between isozymes and is where alternative splicing occurs. 
The C-terminal most domain is the association domain. 
Figure 2. The FLAG elution process eliminates non-specifically boundproteins. Panel A is a 
GFP western blot of the FLAG eluents. Lane 1 is the lysate of the transfected cells and lane 2 
is the first elution and lane 3 is the second. Panel B is a SYPRO Ruby total protein stain of 
the FLAG eluents. The bands at Lane 1 is the lysate of the transfected cells, lane 2 is that first 
eluent and lane 3 is the second. In both images the bands at 25 and 50 kDa correspond to the 
IgG light and heavy chains and the band at 80 kDa is the M, of FLAG/mGGEWT. It is clear 
that the majority of the proteins are cleared from the lysate. 
Fli-I lntegrin 
Immunoprecipitating Antibody 
Figure 3.  Reciprocal IP of endogenous C a m - 1 1  and Fli-I. In panel A, CaMK-I1 antibodies 
were used against untreated lystates. Lane 1 is whole cell lysates, lane 2 is a P CaMK-I1 
antibody and lane 3 is a 6 CaMK-I1 antibody immunoprecipitation of whole cell lystate. All 
three were probed with an anti-Fli-I antibody and show a band in the 145 kDa region, 
corresponding to the M, of Fli-I. Panel B shows a Fli-I LP that was probed with biotinylated 
CaM. Lane 1 is whole cell lysate and lane 2 is a FIi-I IP. There are multiple bands in the 54- 
60 kDa region, representative of the mass of various CaMK-I1 isozymes. Panel C shows a 
graph of the amount of CaMK-I1 activity that was recovered from a Fli-I IP as compared to an 
integrin LP, which is known to not bind CaMK-11. 
Figure 4. C a m - 1 1  activity dependent association with Fli-I. N M  3T3 cells were 
transfecterd with FLAGIGFP-tagged GE CaMK-11. In panel A, lane 1 is non- 
immunoprecipitated untransfected lysate to illustrate input, lane 2 is FLAG/mGGEWT, lane 3 
is FLAGlmGGECon, lane 4 is FLAG/mGGEWT with 10 pM kn-93, and lane 5 is 
FLAG/mGGEWT with 10 pM mAIP. Lanes 2-5 were immunprecipitated using an anti-GFP 
antibody then western blotted for Fli-I. Lane 3, has more Fli-I associated then does the 
control, lane 2 and much more than the lanes 4 and 5, the CaMK-I1 inhibited samples. The 
relative amounts of CaMK-I1 expressed in the samples as determined enzymatically are 
represented in panel B. It is intersting to note that the KN-93 and mAIP treated samples are 
expressed at a much higher level, but had much less Fli-I and F L A G / ~ G G E C O ~  was the 
lowest and had the most Fli-I bound. Panel C shows the CaMK-I1 autonomy of the samples 
and illustrates that greater autonomy, which corresponds to greater quantity of Fli-I 
Figure 5.  Fli-I localization in NIH 3T3 cells. Fli-I can be specifically visualized in NIH 3T3 
cells using Texas Red conjugated anitbodies. Fli-I is a very dynamic molecule that localizes 
in a variety of patterns that are correlated to the cell's activities. It can be entirely in the 
cytosol in cells that are motile and active (panel A). Fli-I can also assume a heterogenous 
localization pattern, both in and out of the nucleus, in a single culture (panel B). It can also 
be primarily nuclear, which is suggestive of cell arrest (panel C). Scale bar represents 50 pm. 
Figure 6. Fli-I localizes to the nucleus in arrested cells. During times of activity Fli-I is 
found outside of the nucleus and associating with actin based structures (panel A). When 
cells arrest is induced with serum starvation, Fli-I begins to translocate to nucleus and can be 
visualized there within 6 hours (panel B). Twelve hours after serum starvation, the majority 
of Fli-I is in the nucleus and that which remains in the nucleus is nonspecifically localized 
(panel C). If arrect is induced by contact, N M  3T3 cells arrest. Cells at a high density have 
Fli-I localized to the nucleus and cytosolically in an undefined manner (panel D). Scale bar 
represents 50 pm. 
Figure 7. Fli-I exits the nucleus in serum stimulated cells. Fli-I is sequestered in the nucleus 
of serum starved cells (panel A). If these cells are stimulated with serum containing medium, 
FIi-I can begin to be seen localizing along actin based structures in the cytosol within 6 hours 
(panel b). Twelve hours after stimulation, Fli-I can still be visualized in the nucleus, but at a 
lower instensity and more dynamically in the cytosol (panel C). Eighteen hours after serum 
has been added to the culture all of the Fli-I has translocated to the cytosol and is associated 
with actin structures and alond the cell edges (panel D). Scale bar represents 50 pm. 
Figure 8. KN-93 causes Fli-I to translocate to the nucleus. NIH 3T3 cells that are active 
exhibit cytosolic Fli-I localization patters (panel A). If these cells are treated with 10 pM 
KN-93, Fli-I begins to be transported into the nucleus and can be seen there within 4 hours of 
treatment (panel B). Twelve hours after KN-93 is added to the culture the majority of Fli-I is 
localized to the nucleus, though some remains outside the nucleus, but is less specifically 
localized (panel C). Eighteen hours post-treatment Fli-I is sequestered to the nucleus (panel 
D). Scale bar represents 50 pm. 
Figure 9. Fli-I is sequestered to the nucleus by mAIP CaMK-TI Inhibition. In a manner very 
similar to treatment with KN-93, 10 mAlP causes Fli-I to translocate to the nuclues. It 
associates with various structures in the cytosol in active cells (panel A). 90 minutes after 
active cells are treated with mAIP much of the cell's Fli-I has moved into the nucleus (panel 
B). Three hours after the mAIP treatment, Fli-I has become sequestered in the cell's nucleus 
(panel C). Scale bar represents 50 p.m. 
Figure 10. Fli-I is not sequestered to the nucleus in arrested cells when CaMK-II artzficially 
activated. In serum free conditions FIi-I is sequestered to the nucleus. It is possible to 
reverse this localization by treating cells with the ca2+ ionophore ionomycin which artifically 
activates CaMK-11. Prior to treatment with ionomycin, FIi-I is localized in the nucleus in 
serum free conditions (Panel A). When the culture is treated with ionomycin for 12 hours, a 
cytosolic presence of Fli-I can begin to be seen (Panel B). 18 hours after the treatment with 
ionomycin all of the cell's Fli-I in the cytosol and is in the regions where it is found in the 
cell's cytosol even though the cells are arrested (Panel C). 
Figure I I .  Potential Model of CaMK-II and Fli-IS interaction. A potential graphical 
representation of the CaMK-11-Fli-I interaction. When ca2' rises in the cell, it becomes 
bound by the ca2+ binding protein CaM. c a 2 ' / c a ~  is bound by CaMK-11 and becomes 
catalytically active. In its active state CaMK-11 is capable of binding Fli-I, which is otherwise 
sequestered to the nucleus. When Fli-I exits the nucleus and CaMK-I1 is active they associate 
and travel to actin filaments throughout the cell and at its edges. 
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